Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEASON: PEG-IFN/Ribavirin in SEA Hepatitis C Patients
NCT00255008Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- Dec 2007
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection (4 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response. Started Mar 2005; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00255008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255008.